Y. Huber

发表

Applicability of a Web-Based, Individualized Exercise Intervention in Patients With Liver Disease, Cystic Fibrosis, Esophageal Cancer, and Psychiatric Disorders: Process Evaluation of 4 Ongoing Clinical Trials

P. Jung, P. Simon, K. Poplawska, 2018, JMIR research protocols.

Improvement of non‐invasive markers of NAFLD from an individualised, web‐based exercise program

K. Clément, M. Karsdal, P. Galle, 2019, Alimentary pharmacology & therapeutics.

Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosis.

P. Galle, J. Schattenberg, C. Labenz, 2020, European journal of internal medicine.

Epidemiology of hepatic encephalopathy in german hospitals – the EpHE study

P. Galle, J. Schattenberg, C. Labenz, 2017, Zeitschrift für Gastroenterologie.

Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors.

D. Schuppan, P. Galle, A. Waisman, 2016, Journal of hepatology.

Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population‐Based Study in Germany

M. Beutel, I. Schmidtmann, P. Wild, 2022, Hepatology communications.

P. Galle, J. Schattenberg, C. Labenz, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4

K. Schulze-Osthoff, M. Bahr, M. Rau, 2022, Journal of clinical medicine.

Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies

J. Schattenberg, C. Labenz, J. Marquardt, 2020, Zeitschrift für Gastroenterologie.

Validation of the simplified Animal Naming Test as primary screening tool for the diagnosis of covert hepatic encephalopathy.

P. Galle, J. Schattenberg, C. Labenz, 2019, European journal of internal medicine.

Development and Validation of a Prognostic Score to Predict Covert Hepatic Encephalopathy in Patients With Cirrhosis

P. Galle, J. Schattenberg, C. Labenz, 2019, The American journal of gastroenterology.

Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany

P. Galle, J. Schattenberg, K. Kostev, 2019, Digestive Diseases and Sciences.

Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV

J. Schattenberg, C. Labenz, Y. Huber, 2022, AIDS.

Tumor Incidence in Patients with Non-Alcoholic Fatty Liver Disease.

P. Galle, J. Schattenberg, K. Kostev, 2020, Deutsches Arzteblatt international.

P. Galle, A. Grambihler, J. Schattenberg, 2021, Quality of Life Research.

Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV

J. Schattenberg, C. Labenz, Y. Huber, 2022, Hepatology communications.

Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low‐Density Lipoprotein Cholesterol

P. Galle, P. Wild, J. Schattenberg, 2019, Hepatology communications.

Nonalcoholic Fatty Liver Disease Increases the Risk of Anxiety and Depression

P. Galle, J. Schattenberg, K. Kostev, 2020, Hepatology communications.

Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters – an animal model of life style intervention in NAFLD

P. Galle, P. Simon, J. Schattenberg, 2019, Scientific Reports.

GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis.

T. Berg, G. Gerken, A. Canbay, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Hepatic B cell leukemia-3 suppresses chemically-induced hepatocarcinogenesis in mice through altered MAPK and NF-κB activation

P. Galle, A. Waisman, J. Schattenberg, 2016, Oncotarget.

Adipokines and Endotoxemia Correlate with Hepatic Steatosis in Non-Alcoholic Fatty Liver Disease (NAFLD)

J. Schattenberg, C. Labenz, I. Bergheim, 2020, Nutrients.

PuraStat in gastrointestinal bleeding: results of a prospective multicentre observational pilot study

B. Wiedenmann, A. Adler, A. Stroux, 2021, Surgical Endoscopy.

Voluntary distance running prevents TNF-mediated liver injury in mice through alterations of the intrahepatic immune milieu

D. Schuppan, P. Galle, P. Simon, 2017, Cell Death & Disease.

Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

P. Galle, J. Schattenberg, C. Labenz, 2017, Digestive Diseases.

Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study

P. Simon, D. Pfirrmann, J. Schattenberg, 2019, Journal of medical Internet research.

Prospective evaluation of the impact of covert hepatic encephalopathy on quality of life and sleep in cirrhotic patients

P. Galle, J. Schattenberg, C. Labenz, 2018, Alimentary pharmacology & therapeutics.

Predictors of advanced fibrosis in non‐cirrhotic non‐alcoholic fatty liver disease in Germany

D. Schuppan, P. Galle, J. Schattenberg, 2018, Alimentary pharmacology & therapeutics.

P. Galle, J. Schattenberg, C. Labenz, 2019, European journal of internal medicine.

Raised serum Interleukin‐6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy

P. Galle, J. Schattenberg, C. Labenz, 2019, Alimentary pharmacology & therapeutics.

Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer

P. Galle, J. Marquardt, R. Kloeckner, 2021, JHEP reports : innovation in hepatology.

Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study (Preprint)

P. Simon, D. Pfirrmann, J. Schattenberg, 2018 .

Validation of insulin-like growth factor-1 as a prognostic parameter in patients with hepatocellular carcinoma in a European cohort

P. Galle, I. Schmidtmann, C. Labenz, 2018, BMC Cancer.

Voluntary exercise in mice fed an obesogenic diet alters the hepatic immune phenotype and improves metabolic parameters – an animal model of life style intervention in NAFLD

P. Galle, P. Simon, J. Schattenberg, 2019, Scientific Reports.

SAT-349-Improvement of hepatic inflammation and fibrosis independently of weight loss from a short, individualized, web-based exercise program in patients with NAFLD

P. Galle, P. Simon, D. Pfirrmann, 2019, Journal of Hepatology.

Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study

P. Simon, D. Pfirrmann, J. Schattenberg, 2019, Journal of medical Internet research.

Web-Based Exercise as an Effective Complementary Treatment for Patients With Nonalcoholic Fatty Liver Disease: Intervention Study (Preprint)

P. Simon, D. Pfirrmann, J. Schattenberg, 2018 .

Welches (ist das richtige) Target bei nichtalkoholischer Fettleber (NAFLD)

P. Galle, Y. Huber, J. Schattenberg, 2020, Zeitschrift für Gastroenterologie.